혈장 분획 시장 : 제품 유형, 분획 방법, 용도, 최종사용자별 - 시장 예측(2026-2032년)

The Plasma Fractionation Market is projected to grow by USD 78.28 billion at a CAGR of 9.97% by 2032.

Plasma fractionation converts donated human plasma into plasma-derived medicinal products, including immunoglobulins, albumin, coagulation factors, protease inhibitors, and specialty therapies used across immunology, hematology, neurology, critical care, trauma care, and rare disease management. These biologics remain clinically essential because they are manufactured from human plasma proteins and cannot be fully substituted by conventional small-molecule medicines.

The sector is structurally supply-sensitive because output depends on qualified plasma collection, strict donor eligibility screening, validated pathogen reduction and viral inactivation, cold-chain integrity, and regulated manufacturing yield. Demand is anchored in diagnosed primary immunodeficiency, immune-mediated neurological disorders, hemophilia, liver disease, burns, shock, and expanding clinical use of immunoglobulin therapy under evidence-based treatment guidelines.

Transformative Shifts in the Plasma Fractionation Landscape

The plasma fractionation landscape is shifting from capacity expansion alone toward resilient, regionally diversified supply chains. Governments, blood systems, and manufacturers are prioritizing plasma self-sufficiency, long-term collection partnerships, donor retention programs, and upgraded fractionation capacity to reduce exposure to donor shortages, logistics disruption, and cross-border dependency.

Clinical practice is also evolving. Subcutaneous immunoglobulin, extended-half-life coagulation therapies, improved pathogen safety technologies, better rare disease diagnosis, and broader neurologic indications are changing product mix. At the same time, regulatory scrutiny, hemovigilance, traceability requirements, environmental expectations, and sustainability reporting are raising the operating bar for plasma collection centers and global plasma fractionation facilities.

Cumulative Impact of Artificial Intelligence on Plasma Fractionation

Artificial intelligence is increasingly relevant across donor operations, production planning, quality assurance, logistics, and pharmacovigilance. AI-enabled analytics can support donor appointment optimization, donor retention modeling, batch deviation detection, inventory allocation, cold-chain monitoring, equipment maintenance, and early identification of adverse event signals from post-marketing safety data.

In a highly regulated biologics environment, AI adoption must remain validated, explainable, and compliant with GxP, data integrity, privacy, cybersecurity, and medical product safety requirements. The strongest use cases augment expert decision-making rather than replace it, improving consistency, speed, documentation quality, and risk visibility across the plasma value chain from collection to patient access.

Key Regional Insights Across Global Plasma Fractionation

North America remains pivotal due to its extensive source plasma collection infrastructure, established reimbursement pathways, advanced specialty care networks, and concentration of global fractionation expertise. The United States has a large donor-center base and strong immunoglobulin utilization, while Canada continues to emphasize secure access through regulated blood and plasma systems. Europe combines mature clinical adoption with strong oversight from national agencies and regional regulators, and policy discussions increasingly emphasize strategic autonomy, donor safety, traceability, and secure access to critical plasma-derived medicinal products across the European Union, the United Kingdom, and other European markets.

Asia-Pacific is expanding through rising diagnosis rates, hospital infrastructure investment, aging populations, and government interest in domestic plasma collection and fractionation capacity, particularly in China, India, Japan, South Korea, and Australia. Latin America is advancing through Brazil- and Mexico-led specialty care demand, with access shaped by public procurement, reimbursement policies, and import dependency. The Middle East, especially GCC states, is investing in healthcare modernization, national specialty treatment programs, and secure procurement channels. Africa remains underpenetrated, with access constrained by affordability, diagnostic availability, cold-chain capacity, plasma collection infrastructure, and reliance on imported plasma-derived therapies.

Key Group Insights for Plasma Fractionation Demand

The European Union is central to regulatory harmonization, donor safety standards, pharmacovigilance, and policy discussions on plasma self-sufficiency for plasma-derived medicinal products. G7 countries anchor advanced demand through mature healthcare systems, specialist physician networks, rare disease diagnosis, biologics reimbursement, and high clinical use of immunoglobulin, albumin, and coagulation therapies. NATO countries increasingly view plasma-derived therapies through the lens of medical preparedness, emergency response, and health security, particularly for trauma care, critical care, and continuity of supply during crises.

BRICS economies represent an important structural growth pathway as China, India, Brazil, Russia, and South Africa expand healthcare access, diagnostics, and domestic biomanufacturing capabilities. ASEAN markets are progressing through hospital upgrades, private healthcare growth, national insurance expansion, and stronger specialty care capacity, although access remains uneven across member states. GCC countries are accelerating centralized procurement, local partnerships, healthcare infrastructure investment, and national programs intended to reduce dependence on imported plasma products while improving access to immunology, hematology, and critical care therapies.

Key Country Insights in Plasma Fractionation

The United States is the global center of source plasma collection and a leading user of immunoglobulin therapy, supported by specialty pharmacy channels, diagnosis of immune deficiencies, and broad clinical adoption. Canada emphasizes secure supply and regulated access through national blood and plasma governance. Mexico and Brazil show rising demand tied to expanding specialty care, public health procurement, and improved recognition of immunodeficiency and hematology conditions. In Europe, the United Kingdom, Germany, France, Italy, and Spain remain important plasma fractionation markets supported by universal healthcare structures, clinical guidelines, hospital networks, and established use of immunoglobulins, albumin, and coagulation factors.

Russia maintains domestic production priorities and seeks to strengthen supply security, while China is scaling plasma collection, fractionation capacity, and diagnosis of immune-mediated diseases under close regulatory oversight. India is advancing through hospital expansion, growing critical care needs, and increasing attention to domestic plasma utilization, though collection and access remain development priorities. Japan, Australia, and South Korea combine advanced regulation, high clinical standards, aging populations, and strong hospital systems, supporting demand for immunoglobulin, albumin, coagulation products, and specialty plasma therapies used in complex disease management.

Actionable Recommendations for Plasma Fractionation Leaders

Industry leaders should strengthen plasma supply resilience through diversified collection networks, long-term donor engagement, digital scheduling, donor education, ethical recruitment practices, and contingency planning. Investment in fractionation yield, pathogen safety, cold-chain visibility, automated quality systems, validated analytics, and manufacturing redundancy remains essential as regulators and healthcare providers prioritize reliability, traceability, and uninterrupted access.

Commercial strategies should align product portfolios with immunoglobulin demand, albumin access, rare disease diagnosis, hemophilia care, and regional plasma self-sufficiency programs. Leaders should deploy validated AI, expand clinician education, support earlier diagnosis, pursue strategic public-private partnerships, and build transparent evidence packages that support reimbursement, patient access, tender success, and differentiated value in plasma-derived medicinal products.

Research Methodology for Plasma Fractionation Analysis

This executive summary is developed through triangulation of public regulatory guidance, clinical literature, health agency materials, reimbursement context, donor and blood system information, manufacturing disclosures, and observed industry investment patterns. Sources typically include authorities such as the FDA, EMA, WHO, national blood agencies, pharmacovigilance databases, peer-reviewed journals, and audited public reporting.

The methodology emphasizes verified, data-backed signals over speculative claims. Insights are evaluated across product type, therapeutic use, plasma collection capacity, manufacturing footprint, quality and safety requirements, regional access, public policy direction, reimbursement conditions, and competitive strategy to provide an objective view of the plasma fractionation ecosystem without relying on market sizing or forecasting.

Conclusion on the Future of Plasma Fractionation

Plasma fractionation is becoming more strategic as demand for immunoglobulins, albumin, coagulation factors, protease inhibitors, and specialty plasma therapies intersects with rare disease care, critical care, health security, and biologics manufacturing resilience. The sector's future will be shaped by plasma availability, donor safety, regulatory discipline, product evidence, and the ability to maintain trusted supply chains.

The strongest organizations will combine reliable plasma sourcing, operational excellence, validated digital intelligence, robust quality systems, and patient-centered access strategies. As regional self-sufficiency initiatives and healthcare preparedness priorities accelerate, the industry will increasingly reward stakeholders capable of delivering safe, reliable, traceable, and evidence-supported plasma-derived medicines across diverse healthcare settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Plasma Fractionation Market, by Product Type

• 7.1. Albumin
• 7.2. Coagulation Factor Concentrates
• 7.3. Immunoglobulins
  • 7.3.1. Intravenous Immunoglobulin
  • 7.3.2. Subcutaneous Immunoglobulin
• 7.4. Protease Inhibitors

8. Plasma Fractionation Market, by Method of Fractionation

• 8.1. Centrifugation
• 8.2. Cryoprecipitation
• 8.3. Ethanol Precipitation
• 8.4. Ion-Exchange Chromatography
• 8.5. Ultrafiltration

9. Plasma Fractionation Market, by Application

• 9.1. Hematology
• 9.2. Neurology
• 9.3. Oncology
• 9.4. Rheumatology

10. Plasma Fractionation Market, by End-User

• 10.1. Academic Institutions
• 10.2. Clinical Research Laboratories
• 10.3. Hospitals & Clinics

11. Plasma Fractionation Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Plasma Fractionation Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Plasma Fractionation Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 3M Company
• 15.2. ADMA Biologics, Inc.
• 15.3. Bharat Serums and Vaccines Limited
• 15.4. Bio Products Laboratory Ltd.
• 15.5. Biotest AG by Grifols, S.A.
• 15.6. China Biologic Products, Inc.
• 15.7. CSL Limited
• 15.8. Emergent BioSolutions Inc.
• 15.9. GC Biopharma corp.
• 15.10. HEINKEL Process Technology GmbH
• 15.11. Hemarus Therapeutics Ltd
• 15.12. Intas Pharmaceuticals Ltd.
• 15.13. Kamada Ltd.
• 15.14. Kedrion S.p.A.
• 15.15. LFB SA
• 15.16. Merck KGaA
• 15.17. Octapharma AG
• 15.18. PlasmaGen BioSciences Pvt. Ltd.
• 15.19. Prothya Biosolutions B.V.
• 15.20. Shanghai Raas Blood Products Co. Ltd.
• 15.21. SK Plasma Co.,Ltd.
• 15.22. STERIS plc
• 15.23. Takeda Pharmaceutical Company Ltd.